

Figure S1. Representative flow cytometry dot plots of the proportion of peripheral blood Th1 (IFN- γ^+), Th2 (IL-4⁺), Th17 (IL-17⁺) and Th22 (IL-22⁺) cells of patients with atopic dermatitis treated with dupilumab. Th, T helper.




Figure S2. Representative flow cytometry dot plots of the proportion of T helper 2 (IL-4⁺) cells in patients with atopic dermatitis treated with dupilumab, categorized by Eczema Area and Severity Index (EASI) grades (mild, moderate or severe) at weeks 0, 2, 4 and 8. The boxes in the dot plots correspond to the gated areas indicating the proportion of Th2 cells (expressing IL-4). FSC, forward scatter.




Figure S3. Representative flow cytometry dot plots of T helper 17 (IL-17⁺) cell ratios in (A) intra-group and (B) inter-group analysis for rapid and slow therapeutic effects at weeks 0, 2, 4 and 8. The boxes in the dot plots correspond to the gated areas indicating the proportion of Th17 cells (expressing IL-17). FSC, forward scatter.

